Combined inhibition of BTK and PI3Kδ triples the survival advantage and reduces NF-κB signaling, compared with single agents in an aggressive murine CLL model, supporting the continuation of clinical trials with the combination of BTK and PI3Kδ inhibitors.
Introduction
Chronic Lymphocytic Leukemia (CLL) is the most common leukemia in western countries with more than 15,000 newly diagnosed cases each year in the US alone. (1) In vitro studies with ibrutinib and idelalisib demonstrated synergy of combined PI3Kδ and BTK inhibition. (11, 12) However, in vivo data on the efficacy of combined PI3Kδ and BTK inhibition are missing. Acalabrutinib is a novel, potent and highly selective BTK inhibitor that, like ibrutinib, binds covalently to Cys481 in the ATP-binding pocket and has shown similar efficacy in murine models of CLL. (13) In a phase I/II clinical trial, acalabrutinib had an objective response rate of 95% at median follow-up of 14.3 months and 90% progression-free survival at 18 months. (14) ACP-319 (AMG319), a novel PI3Kδ inhibitor, was tolerable and showed promising activity in a phase I trial with 13/15 CLL patients remaining on treatment after a median follow up of 30 weeks. (15) 5
Because of the critical importance of the tumor-microenvironment in the pathogenesis of CLL, in vivo models that recapitulate tumor-microenvironment interactions are valuable tools to investigate the effects of targeted agents. (2, 13, (16) (17) (18) (19) ) Therefore, we investigated the combination of acalabrutinib and ACP-319 in a murine CLL model derived from the well-established transgenic Eμ-TCL1 (TCL1) mouse model. (20) Through serial passaging of Eμ-TCL1 splenocytes in immunodeficient mice, a BCR-dependent cell line, TCL1-192, was derived. Adoptive transfer of TCL1-192 cells into immunodeficient mice leads to the development of an aggressive CLL-like disease resulting in death within five to six weeks. (18) Herein, we utilized a murine model of CLL to investigate the efficacy and on-target effects of dual PI3Kδ and BTK inhibition in vivo by ACP-319 and acalabrutinib. Our data demonstrates a significant benefit of combination treatment, which is likely due to more potent inhibition of survival mechanisms that result in increased tumor cell death.
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Materials and Methods
Murine allotransplant of CLL-like TCL1-192 cells
All animal handling and housing followed the guidelines set forth by the animal care and use committee of the NHLBI. Allografting of TCL1-192 cells (provided by N. Chiorazzi) (18) into NOD-SCID mice (Jackson Laboratory) was carried out as previously described. (18) Briefly, 5x10 6 freshly thawed TCL1-192 splenic cells, in PBS, were injected retro-orbitally into 16-20 mice recipient mice for each experimental cohort, split equally between four treatment groups, vehicle, acalabrutinib, ACP-319 and combination. TCL1-192 cell proliferation (leukemia) in peripheral blood was proven by flow cytometry one or two weeks after cell injection.
Treatment of mice with kinase inhibitors or vehicle and handling of samples
Treatment for TCL1-192 allografted NOD-SCID mice was initiated 7-21 days after cell injection with drinking water (provided by Acerta Pharma, Redwood City, CA, USA) containing vehicle (2% w/v HPβCD) and 0.15 mg/mL acalabrutinib, vehicle and ACP-319 0.15 mg/mL, a combination of the two drugs or vehicle alone. This regimen results in an average daily dose of 25 mg/kg of each drug. (3, 19) TCL1-192 allografted mice were bled weekly or biweekly and followed for survival until death or predetermined morbidity endpoints, with the exception of two cohorts that were sacrificed four weeks post cell injection. Peripheral blood (PB) and spleens were harvested at sacrifice.
Single-cell suspensions of splenocytes were obtained by manually homogenizing spleens and filtering through 70 nm nylon sieves (BD Falcon, Franklin Lakes, NJ, USA). Cells were analyzed immediately after erythrocyte lysis using ACK buffer (Quality Biological, Inc., Gaithersburg, MD, USA). 
Flow cytometry
Statistical analysis
To compare treatment effect across mice, an unpaired t-test was applied taking into account the random batch effect (JMP, SAS, Cary, NC, USA). For survival analysis, estimates of overall survival were obtained using the Kaplan-Meier method, and the log-rank test (Mantel-Cox) was used to evaluate differences between curves (Prism 6). 
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